Industry Leaders Call for Reforms to Unlock Local Drug Manufacturing and Healthcare Growth

Nigeria’s pharmaceutical industry has long been viewed as one of the country’s most strategic sectors, with the potential to improve healthcare access, reduce import dependence, create jobs, and strengthen economic resilience. Yet despite growing demand for medicines and healthcare products, industry operators continue to face significant policy and operational challenges.

At its recent Annual General Meeting (AGM), May & Baker Nigeria Plc highlighted several policy barriers that continue to limit the growth and competitiveness of the pharmaceutical sector. The company used the platform not only to review its performance but also to draw attention to broader industry concerns affecting manufacturers across the country.

The discussions underscored a growing consensus within the healthcare and manufacturing sectors: without targeted policy reforms, Nigeria may struggle to fully realize its ambition of becoming a pharmaceutical manufacturing hub for Africa.

A Strategic Industry Facing Structural Challenges

The pharmaceutical industry plays a critical role in national development. Beyond producing medicines, the sector supports public health, drives industrialization, creates skilled employment, and contributes to economic diversification.

However, pharmaceutical manufacturers continue to operate in a challenging environment characterized by high production costs, foreign exchange pressures, regulatory bottlenecks, and infrastructure deficits.

According to industry stakeholders, these obstacles have increased operational expenses and reduced the competitiveness of locally manufactured products compared to imported alternatives.

As a result, many manufacturers are calling for stronger government support to encourage domestic production and reduce reliance on imported medicines.

Foreign Exchange and Rising Production Costs

One of the biggest concerns raised during the AGM was the impact of foreign exchange volatility on pharmaceutical manufacturing.

Many raw materials, active pharmaceutical ingredients (APIs), equipment, and production inputs are imported, making manufacturers highly vulnerable to currency fluctuations.

The depreciation of the naira in recent years has significantly increased production costs, placing pressure on profit margins and product pricing.

For companies operating within a highly regulated sector where affordability remains a critical issue, managing these rising costs has become increasingly difficult.

Industry leaders argue that improved access to foreign exchange and policies that encourage local production of pharmaceutical inputs could help reduce these challenges.

The Need for Stronger Industrial Policies

May & Baker’s observations reflect broader concerns within Nigeria’s manufacturing sector.

Stakeholders continue to advocate for policies that support local production through tax incentives, infrastructure development, access to affordable financing, and regulatory reforms.

Industry experts believe that strengthening local pharmaceutical manufacturing would not only improve healthcare security but also reduce Nigeria’s dependence on imported drugs.

The COVID-19 pandemic exposed vulnerabilities in global supply chains, highlighting the importance of domestic manufacturing capabilities for essential healthcare products.

Since then, many African countries have intensified efforts to build stronger local pharmaceutical industries capable of responding to future healthcare emergencies.

Opportunities Under AfCFTA

The African Continental Free Trade Area (AfCFTA) presents significant opportunities for pharmaceutical manufacturers across the continent.

With a market of more than 1.4 billion people, African pharmaceutical companies have the potential to expand beyond national borders and serve regional markets.

For Nigerian manufacturers, increased competitiveness could unlock export opportunities and position the country as a leading supplier of medicines within Africa.

However, industry leaders emphasize that achieving this goal will require supportive policies, improved infrastructure, and a business environment that encourages long-term investment.

Healthcare, Manufacturing, and Economic Growth

The pharmaceutical sector sits at the intersection of healthcare and industrial development.

A stronger local industry could improve access to essential medicines, reduce healthcare costs, stimulate research and development, and create thousands of jobs across the value chain.

It could also attract foreign direct investment and strengthen Nigeria’s position within Africa’s growing healthcare economy.

As governments seek to diversify their economies and strengthen healthcare systems, pharmaceutical manufacturing is increasingly viewed as a strategic sector capable of delivering both social and economic benefits.

The concerns raised at May & Baker’s AGM reflect a larger conversation about Africa’s industrial future.

The continent cannot achieve healthcare independence while remaining heavily dependent on imported medicines and pharmaceutical inputs. Building a competitive pharmaceutical sector requires more than private sector investment—it requires deliberate policy support, regulatory efficiency, and long-term strategic planning.

For Nigeria and Africa, the opportunity is clear. With the right reforms, the pharmaceutical industry could become a major driver of industrial growth, healthcare security, job creation, and regional trade.

The challenge now is turning policy discussions into action.

Because the future of healthcare in Africa will depend not only on access to medicines, but on the continent’s ability to manufacture them.